As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
News|Articles|October 2, 2026
5 Psychiatry Headlines You Missed in September 2026
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
Advertisement
Advertisement
September brought regulatory and research momentum for psychedelic therapies in psychiatry. The US Food & Drug Administration (FDA) granted DT120 (lysergide) orally disintegrating tablet (ODT) a second Breakthrough Therapy designation, this time in
Related to this article
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Advertisement
Advertisement